Serologicals Corporation to Present at 2005 First Analysis Investment Conference
10 Novembre 2005 - 3:14PM
Business Wire
Serologicals Corporation (NASDAQ:SERO) today announced that it is
scheduled to give an investor presentation at the 2005 First
Analysis Investment Conference on November 17, 2005. David A. Dodd,
President and Chief Executive Officer for Serologicals Corporation,
will be making the presentation, scheduled for 10:35 a.m. (ET) at
The New York Palace Hotel in New York City. The presentation will
be web cast live (audio only) and can be accessed through the
Company's website at www.serologicals.com or at
http://www.wsw.com/webcast/fa3/sero/. Serologicals Corporation
(NASDAQ:SERO), headquartered in Atlanta, Georgia, is a global
provider of biological products, enabling technologies and services
to a diverse customer base that includes major life science
companies and leading research institutions. Our customers use our
products, technologies and services in a wide variety of their
activities, including basic research, drug discovery, diagnosis and
biomanufacturing. Our products, technologies and services are
essential tools for research in key disciplines, including
neurology, oncology, hematology, immunology, cardiology,
proteomics, infectious diseases, cell signaling and molecular
biology. In addition, the Company is the world's leading provider
of monoclonal antibodies for the blood typing industry.
Serologicals employs a total of more than 1,000 people worldwide in
three Serologicals' companies: Chemicon International,
headquartered in Temecula, CA, Upstate Group, LLC, headquartered in
Charlottesville, VA. and Celliance Corporation, headquartered in
Atlanta, GA. For more information, please visit our website:
www.serologicals.com. Serologicals is a registered trademark of
Serologicals Royalty Company.
Grafico Azioni Serologicals (NASDAQ:SERO)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Serologicals (NASDAQ:SERO)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Serologicals (MM) (NASDAQ): 0 articoli recenti
Più Serologicals Corporation Articoli Notizie